Background: Acute exacerbations of chronic rhinosinusitis (AECRS) are associated with significant morbidity and decreased quality of life. There are sparse data assessing the real-world impact of biologics on AECRS. Objectives: We sought to determine the impact of type 2-targeting biologics on the frequency of medication use for AECRS episodes. Methods: Antibiotic and/or systemic corticosteroid courses for AECRS were identified in a retrospective study from November 2015 to February 2020, at a single academic health system. The estimated yearly rates for antibiotic and corticosteroid courses were evaluated before and after initiation of type 2 biologics. Results: One-hundred and sixty-five patients with chronic rhinosinusitis (CRS) had received either omalizumab (n = 12), mepolizumab (n = 42), benralizumab (n = 44), dupilumab (n = 61), or reslizumab (n = 6). Seventy percent had CRS with nasal polyps, and 30% had CRS without nasal polyps. All the patients had asthma. When all the biologics were combined, the estimated yearly rate for antibiotics for AECRS decreased from 1.34 (95% confidence interval [CI], 1.12-1.59) to 0.68 (95% CI, 0.52-0.88) with biologic use (49% reduction, p < 0.001). Those with frequent AECRS (three or more courses of antibiotics in the 1 year before biologic use) had a larger degree of reduction, with an estimated yearly rate of 4.15 (95% CI, 3.79-4.55) to 1.58 (95% CI, 1.06-2.35) with biologic use (n = 27; 62% reduction; p < 0.001). Within the total cohort, the estimated yearly rate for systemic corticosteroids for AECRS decreased from 1.69 (95% CI, 1.42-2.02) to 0.68 (95% CI, 0.53-0.88) with biologic use (60% reduction; p < 0.001). Conclusion: Type 2-targeting biologics reduced medication use for AECRS. This suggested that biologics may be a therapeutic option for patients with frequent AECRS.
Background: Acute exacerbations of chronic rhinosinusitis (AECRS) are associated with significant morbidity and decreased quality of life. There are sparse data assessing the real-world impact of biologics on AECRS. Objectives: We sought to determine the impact of type 2-targeting biologics on the frequency of medication use for AECRS episodes. Methods: Antibiotic and/or systemic corticosteroid courses for AECRS were identified in a retrospective study from November 2015 to February 2020, at a single academic health system. The estimated yearly rates for antibiotic and corticosteroid courses were evaluated before and after initiation of type 2 biologics. Results: One-hundred and sixty-five patients with chronic rhinosinusitis (CRS) had received either omalizumab (n = 12), mepolizumab (n = 42), benralizumab (n = 44), dupilumab (n = 61), or reslizumab (n = 6). Seventy percent had CRS with nasal polyps, and 30% had CRS without nasal polyps. All the patients had asthma. When all the biologics were combined, the estimated yearly rate for antibiotics for AECRS decreased from 1.34 (95% confidence interval [CI], 1.12-1.59) to 0.68 (95% CI, 0.52-0.88) with biologic use (49% reduction, p < 0.001). Those with frequent AECRS (three or more courses of antibiotics in the 1 year before biologic use) had a larger degree of reduction, with an estimated yearly rate of 4.15 (95% CI, 3.79-4.55) to 1.58 (95% CI, 1.06-2.35) with biologic use (n = 27; 62% reduction; p < 0.001). Within the total cohort, the estimated yearly rate for systemic corticosteroids for AECRS decreased from 1.69 (95% CI, 1.42-2.02) to 0.68 (95% CI, 0.53-0.88) with biologic use (60% reduction; p < 0.001). Conclusion: Type 2-targeting biologics reduced medication use for AECRS. This suggested that biologics may be a therapeutic option for patients with frequent AECRS.
Authors: A Tiotiu; J P Oster; P R Roux; P L Nguyen Thi; G Peiffer; P Bonniaud; J C Dalphin; F de Blay Journal: J Investig Allergol Clin Immunol Date: 2019-04-01 Impact factor: 4.333
Authors: Shauna Schroeder; Zachary D Robinson; Joanne C Masterson; Lindsay Hosford; Wendy Moore; Zhaoxing Pan; Rachel Harris; Rhonda F Souza; Stuart Jon Spechler; Sophie A Fillon; Glenn T Furuta Journal: Pediatr Res Date: 2013-02-05 Impact factor: 3.756
Authors: Claus Bachert; Joseph K Han; Martin Desrosiers; Peter W Hellings; Nikhil Amin; Stella E Lee; Joaquim Mullol; Leon S Greos; John V Bosso; Tanya M Laidlaw; Anders U Cervin; Jorge F Maspero; Claire Hopkins; Heidi Olze; G Walter Canonica; Pierluigi Paggiaro; Seong H Cho; Wytske J Fokkens; Shigeharu Fujieda; Mei Zhang; Xin Lu; Chunpeng Fan; Steven Draikiwicz; Siddhesh A Kamat; Asif Khan; Gianluca Pirozzi; Naimish Patel; Neil M H Graham; Marcella Ruddy; Heribert Staudinger; David Weinreich; Neil Stahl; George D Yancopoulos; Leda P Mannent Journal: Lancet Date: 2019-09-19 Impact factor: 79.321
Authors: Anju Tripathi; David B Conley; Leslie C Grammer; Anne M Ditto; Margaret M Lowery; Kristen A Seiberling; Paul A Yarnold; Barbara Zeifer; Robert C Kern Journal: Laryngoscope Date: 2004-10 Impact factor: 3.325
Authors: Annemarie G Hirsch; Cara Nordberg; Karen Bandeen-Roche; Bruce K Tan; Robert P Schleimer; Robert C Kern; Agnes Sundaresan; Jayant M Pinto; Thomas L Kennedy; Joseph Scott Greene; Jordan R Kuiper; Brian S Schwartz Journal: Allergy Date: 2019-12-02 Impact factor: 13.146
Authors: Raphael G Banoub; Katie M Phillips; Lloyd P Hoehle; David S Caradonna; Stacey T Gray; Ahmad R Sedaghat Journal: Laryngoscope Date: 2017-09-30 Impact factor: 3.325